CTLA-4 checkpoint inhibitor (PsiOxus Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCTLA-4 checkpoint inhibitor (PsiOxus Therapeutics)
Drug Alias Nametransgene-modified enadenotucirev expressing CTLA-4 checkpoint inhibitor (PsiOxus)CTLA-4 checkpoint inhibitor (PsiOxus Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Oncolytic virus
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAkamis Bio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAkamis Bio Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A